Company news

Axsome Therapeutics, Inc. news in 2024

Axsome Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

December 29, 2024

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

November 7, 2024

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

October 28, 2024

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

October 14, 2024

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

September 3, 2024

Axsome Therapeutics to Participate in Investor Conferences in September

August 26, 2024

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

August 20, 2024

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 4, 2024

Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

July 10, 2024

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

June 4, 2024

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

June 3, 2024

Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

June 2, 2024

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

May 28, 2024

Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting

May 27, 2024

Axsome Therapeutics to Present at Upcoming Investor Conferences

May 7, 2024

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 5, 2024

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

April 30, 2024

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

April 14, 2024

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

April 9, 2024

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

March 31, 2024

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

March 24, 2024

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

March 24, 2024

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

March 18, 2024

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

March 4, 2024

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

February 26, 2024

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 19, 2024

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

January 22, 2024

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

January 3, 2024

Calls in 2024

Decks in 2024